Tracked shipping to Austria with premium packaging for just 3,99 € 

Ship to
Austria
0

My Account

  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

menu

Select your country

Americas

Europe

Rest of the world

portada Drugs for Her-2-Positive Breast Cancer
Type
Physical Book
Publisher
Author
Language
English
Pages
110
Format
Paperback
Dimensions
23.4 x 15.6 x 0.7 cm
Weight
0.18 kg.
ISBN13
9783034803182
Categories

Drugs for Her-2-Positive Breast Cancer

Sibilia, Maria ; Zielinski, Christoph C. ; Bartsch, Rupert (Author) · Springer · Paperback

Drugs for Her-2-Positive Breast Cancer - Sibilia, Maria ; Zielinski, Christoph C. ; Bartsch, Rupert

Cheaper New Book Imported to Austria
Delivery: 12 Aug - 19 Aug Shipping: 12 to 16 business days.
149,60 €
Faster New Book Imported to Austria
Delivery: 31 Jul - 04 Aug Shipping: 4 to 5 business days.
196,76 €
Import costs and 10% VAT included in the price ✅
149,60 €

Choose the list to add your product or create one New List

Go to My Wishlists
Calculate shipping cost

Synopsis "Drugs for Her-2-Positive Breast Cancer"

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

Is the book original?

All books in our catalog are Original.

In what language is the book written?

The book is written in English.

What is the format of this book?

The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews